These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 32065766)
1. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766 [TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer. Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279 [TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis. Yu Q; Xu Y; Yu E; Zheng Z J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740 [TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study. Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379 [TBL] [Abstract][Full Text] [Related]
5. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022 [TBL] [Abstract][Full Text] [Related]
6. Linkage of routinely collected oncology clinical data with health insurance claims data--an example with aromatase inhibitors, tamoxifen, and all-cause mortality. Dore DD; Liang C; Ziyadeh N; Norman H; Bayliss M; Seeger JD Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2():29-36. PubMed ID: 22552977 [TBL] [Abstract][Full Text] [Related]
8. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612 [TBL] [Abstract][Full Text] [Related]
9. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921 [TBL] [Abstract][Full Text] [Related]
10. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789 [TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer. Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897 [TBL] [Abstract][Full Text] [Related]
12. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889 [TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117 [TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Xu X; Chlebowski RT; Shi J; Barac A; Haque R Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431 [TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699 [TBL] [Abstract][Full Text] [Related]
16. Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates. Pineda-Moncusí M; Garcia-Giralt N; Diez-Perez A; Servitja S; Tusquets I; Prieto-Alhambra D; Nogués X J Bone Miner Res; 2020 Feb; 35(2):291-297. PubMed ID: 31596961 [TBL] [Abstract][Full Text] [Related]
17. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. Matthews A; Stanway S; Farmer RE; Strongman H; Thomas S; Lyon AR; Smeeth L; Bhaskaran K BMJ; 2018 Oct; 363():k3845. PubMed ID: 30297439 [TBL] [Abstract][Full Text] [Related]
18. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ; Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698 [TBL] [Abstract][Full Text] [Related]
19. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937 [TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]